- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06024408
A Trial to Learn if Receiving ALN-PNP siRNA is Safe and Well Tolerated, and How it Works in Adult Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a Genetic Risk Factor
A Three-Part, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-PNP siRNA in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) and a PNPLA3 Genetic Risk Factor
This study is researching an experimental drug called ALN-PNP. This study is focused on participants who are known to have nonalcoholic fatty liver disease (NAFLD), and a specific variant of the patatin-like phospholipase domain containing 3 (PNPLA3) gene.
The aim of this study is to see how safe, tolerable, and effective the study drug is.
This study is looking at several other research questions, including:
- What side effects may happen from taking the study drug
- How the study drug works to change liver fat content in NAFLD
- How much study drug and study drug metabolites (byproduct of the body breaking down the study drug) are in your blood at different times
- Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
- Better understanding of the study drug and NAFLD
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Trials Administrator
- Phone Number: 844-734-6643
- Email: clinicaltrials@regeneron.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Participants from 18 (or country's legal age of adulthood) to 65 years of age, inclusive, at screening visit 1
- Body mass index (BMI) from 23.0 kg/m^2 to 40.0 kg/m^2, inclusive, for East Asians (including but not limited to South Koreans, Chinese, Taiwanese, and Japanese) and BMI from 27.0 kg/m^2 to 40.0 kg/m^2, inclusive, for any other ethnicity at screening visit 1
- Meets genotype criteria for the rs738409:G PNPLA3 risk allele: homozygotes (for Part A and Part B) or heterozygotes (optional Part C); p.I148M variant (PNPLA3 rs738409:G [p.I148M]) at screening visit 1
- Liver fat content ≥8.5% as measured by MRI-PDFF at screening visit 3
- Generally stable diet (based on participant's recall) for at least 3 months prior to the screening visit
Key Exclusion Criteria:
- Evidence of other forms of known chronic liver disease, as defined in the protocol
- Has a contraindication to MRI examinations, such as persons with cardiac pacemaker and implants made out of metal (for example, cochlear implant, nerve stimulators, magnetic vascular clips, and metallic heart valve), severe claustrophobia, or other contraindications for MRI
- Is taking a medication to treat a co-morbid condition that is not permitted during the study
- Has any laboratory parameter assessments at screening, as defined in the protocol
- History of Type 1 diabetes
- Bariatric surgery within approximately 5 years prior or planned during the study period
- Has lost or gained more than 4.0% body weight over the 3 months prior to or during the screening period
- Has known human immunodeficiency virus (HIV) infection, evidence of current or chronic hepatitis B virus (HBV) infection, or current or chronic hepatitis C virus (HCV) infection, as defined in the protocol
- Was hospitalized (ie, >24 hours) for any reason within 30 days of the screening visit
Note: Other protocol defined Inclusion/Exclusion Criteria apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Part A: Placebo
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Experimental: Part A: Low Dose
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Experimental: Part A: Mid Dose
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Experimental: Part A: High Dose
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Placebo Comparator: Part B: Placebo
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Experimental: Part B : Low Dose
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Experimental: Part B: Mid Dose
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Experimental: Part B: High Dose
Participants who are homozygous for the PNPLA3 rs738409:G risk allele will be randomized 1:1:1:1
|
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Placebo Comparator: Part C: Placebo (Optional)
Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
|
Part A: Administered as single SC injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
Experimental: Part C: High Dose (Optional)
Sponsor may elect to enroll participants who are heterozygous for the PNPLA3 rs738409:G risk allele and may be randomized 1:1
|
Part A: Administered as single subcutaneous (SC) injection on day 1 Part B and Part C: Administered SC every 12 weeks (Q12W x2)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 253 days
|
Up to 253 days
|
Severity of TEAEs
Time Frame: Up to 253 days
|
Up to 253 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Concentration of ALN-PNP and potential major metabolite(s) in plasma over time
Time Frame: Up to 253 days
|
Up to 253 days
|
Incidence of anti-drug antibodies (ADAs) to ALN-PNP
Time Frame: Up to 253 days
|
Up to 253 days
|
Titer of anti-drug antibodies (ADAs) to ALN-PNP
Time Frame: Up to 253 days
|
Up to 253 days
|
Change in liver fat fraction by magnetic resonance imaging proton density fat fraction (MRI-PDFF) in participants with NAFLD
Time Frame: Baseline up to 253 days
|
Baseline up to 253 days
|
Change in low-density lipoprotein cholesterol (LDL-C) in participants with NAFLD
Time Frame: Baseline up to 253 days
|
Baseline up to 253 days
|
Change in high-density lipoprotein cholesterol (HDL-C) in participants with NAFLD
Time Frame: Baseline up to 253 days
|
Baseline up to 253 days
|
Change in triglycerides (TG) in participants with NAFLD
Time Frame: Baseline up to 253 days
|
Baseline up to 253 days
|
Change in lipoprotein a (Lp(a)) in participants with NAFLD
Time Frame: Baseline up to 253 days
|
Baseline up to 253 days
|
Change in apolipoprotein A1 (ApoA1) in participants with NAFLD
Time Frame: Baseline up to 253 days
|
Baseline up to 253 days
|
Change in apolipoprotein B (ApoB) in participants with NAFLD
Time Frame: Baseline up to 253 days
|
Baseline up to 253 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Clinical Trial Management, Regeneron Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALN-PNP-NASH-2255
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonalcoholic Steatohepatitis (NASH)
-
Milton S. Hershey Medical CenterNot yet recruitingLiver Diseases | NASH - Nonalcoholic Steatohepatitis | NASH
-
Milton S. Hershey Medical CenterRecruitingExercise | NASH - Nonalcoholic Steatohepatitis | NASH | LiverUnited States
-
Polaris GroupRecruiting
-
Corcept TherapeuticsRecruitingNonalcoholic Steatohepatitis (NASH)United States
-
PerspectumRecruitingNASH - Nonalcoholic SteatohepatitisUnited States
-
Metacrine, Inc.Completed
-
Cascade Pharmaceuticals, IncLaboratory Corporation of AmericaCompletedNonalcoholic Steatohepatitis (NASH)United States
-
Poxel SACompletedNASH - Nonalcoholic SteatohepatitisUnited States
-
RWTH Aachen UniversityCompletedNASH - Nonalcoholic SteatohepatitisSweden, Austria, Germany
-
CymaBay Therapeutics, Inc.TerminatedNASH - Nonalcoholic SteatohepatitisUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States